HUTCHMED (China) (HMDCF) Capital Expenditures (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Capital Expenditures came in at -$2.9 million in Q2 2021, down 44.95% year-over-year from -$5.2 million in Q2 2020, and up 52.83% quarter-over-quarter from -$6.1 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Capital Expenditures (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Capital Expenditures for 4 consecutive years, with -$2.9 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Capital Expenditures fell 44.95% year-over-year to -$2.9 million in Q2 2021; TTM through Jun 2021 was -$13.0 million, a 47.83% decrease from a year earlier, with the FY2025 full-year figure at -$14.1 million, up 21.11% from the prior year.
- Capital Expenditures was -$2.9 million for Q2 2021 at HUTCHMED (China), up from -$6.1 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $9.8 million in Q4 2018 and troughed at -$6.1 million in Q1 2021.
- A 4-year average of -$1.3 million and a median of -$1.9 million in 2019 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures plunged 226.81% in 2019 and rose 20.75% in 2020, its largest moves.
- Over 4 years, Capital Expenditures stood at $9.8 million in 2018, then sank by 130.12% to -$3.0 million in 2019, then surged by 33.21% to -$2.0 million in 2020, then sank by 44.95% to -$2.9 million in 2021.
- The last three Capital Expenditures figures came in at -$2.9 million (Q2 2021), -$6.1 million (Q1 2021), and -$2.0 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -1.87 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -2.86 Mn |
| Mar 31, 2021 | -6.06 Mn |
| Jun 30, 2020 | -1.97 Mn |
| Mar 31, 2020 | -2.09 Mn |
| Dec 31, 2019 | -2.95 Mn |
| Sep 30, 2019 | -1.77 Mn |
| Jun 30, 2019 | -2.49 Mn |
| Mar 31, 2019 | -1.36 Mn |
| Dec 31, 2018 | 9.80 Mn |
| Sep 30, 2018 | -1.35 Mn |
| Jun 30, 2018 | -761,000.00 |
| Mar 31, 2018 | -1.32 Mn |